Health & Biotech
Incannex engages Fortrea for major clinical trial looking at IHL-42X for sleep apnoea
Health & Biotech
MGC Pharma extends working capital runway with $1.25 million raise
Health & Biotech
Stock Insiders: Bioxyne acquires Breathe Life Sciences with consumer favourite brand Dr Watson
Health & Biotech
ScoPo’s Powerplays: ASX health stocks fall but don’t throw the baby out with the bathwater
Health & Biotech
Incannex receives ethics approval to start Phase 2 clinical trial for combination drug for rheumatoid arthritis
Health & Biotech
ASX Health Stocks: Market darling Neuren Pharma jumps 16pc on Acadia worldwide licence
Health & Biotech
Weed Week: Social media platforms scramble to update advertising policies on cannabis products
Health & Biotech
PharmAust nears end point of its Phase 2 dog cancer trial and the outlook seems sunny
Health & Biotech
Melodial Global Health delivers record revenue quarter with 105pc uptick in group sales
Health & Biotech
How Bod Science pulled ahead in the race for Australia’s first over-the-counter CBD
Health & Biotech
ASX Health Stocks: Cannabis stock Little Green Pharma awarded French trial tender for CBD50
Health & Biotech
Incannex plans to redomicile to US with sole NASDAQ listing – we look at the arithmetic
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.